Feedback Share Discussion Threads

[blueball] 12/9/2016 20:32

Not much happening here.

[ashtree2] 12/9/2016 14:38

new to this one and under the radar it would appear.took a small stake today and would be interested to hear from others more in the know.Directors own most of the shares which is normally a good sign.

[lr2] 28/7/2016 22:34

Collaboration with Future Processing

Feedback plc (AIM: FDBK), the medical imaging software company is pleased to announce a large-scale collaboration with Future Processing Sp. z o.o. ("Future Processing"), a software development service provider based in Gliwice, Poland to develop medical imaging software. The collaboration will entail a substantially increased development team working on new products and the sharing of intellectual property and future revenues. This collaboration has resulted from Feedback's assistance with a successful EU grant application made by Future Processing.

In September 2015, Mike Hayball, CEO of Cambridge Computed Imaging Limited, a wholly owned subsidiary of Feedback, ("CCI") and Executive Director of Feedback, and Dr Stephen Brown, COO of CCI, began assisting Future Processing with a grant application to develop an innovative quantitative imaging product. The grant application was subsequently successful and has led to a significant expansion of the Future Processing healthcare team. CCI has had a working relationship with Future Processing since 2005.

The directors of Feedback believe that by CCI working jointly with the Future Processing healthcare team, CCI's existing product portfolio can be improved and new products developed more rapidly including further applications for TexRAD. Although at this stage only a non-binding letter of intent has been agreed, the intention is for the Company to agree formal licences for new software products to be brought to market in 2017/18 under a shared revenue arrangement. In the current financial year, the Company will make substantial savings in software development costs and thereafter expects to benefit from its share of the revenue from sales of the new products.

"This is an exciting opportunity to expand the relationship with Future Processing to build a talented, dynamic team of medical imaging specialists." said Mike Hayball, CEO of CCI.

"We are excited about this joint project. Together with CCI we will develop medical imaging software and bring innovative solutions to the healthcare sector." said Jarosław Czaja, CEO of Future Processing.

[lr2] 18/6/2016 23:10

TexRAD on tour - New Zealand.

[lr2] 17/5/2016 16:55

Not much happening as far as I can see.

Texrad got a mention in the following article on Texture Analysis of Cronh's disease last month but not seen anything more recently. Feedback are making us all wait patiently right now.

[britstox] 17/5/2016 16:10

I know of nothing at the moment but LR2 is pretty good with this stock.

[nick rubens] 14/4/2016 11:53

britstox "Does anyone know of anything coming soon we should or could be expecting?"

I would expect a placing.

[lr2] 13/4/2016 16:49

Small mention at 31:30 on podcast 455.



"software and company is globally recognised as a leader in its field".

[blueball] 04/4/2016 09:05

Cant believe how bad this share is.

[britstox] 29/3/2016 20:18

An RNS would be nice. Does anyone know of anything coming soon we should or could be expecting?

[lr2] 23/2/2016 19:12

Dr Balaji Ganeshan talks about Update and Opportunities.

[the stigologist] 22/2/2016 10:37

Should go sub 1p

[the stigologist] 22/2/2016 07:52

Massively overvalued and very little cash left

[lr2] 12/2/2016 22:05

Texrad analysis references in Crohn's Disease article.

[svenice7] 28/1/2016 19:39

This looks undervalued, im thinking about buying.

[britstox] 21/1/2016 23:57

Thanks LR2. I'm still here!

[kenwrong] 13/1/2016 09:51

Thanks for the heads up on this Andy

[andya99] 04/12/2015 16:37

Society of Cardiac MR (SCMR) is January 27-30 in LA

[andya99] 04/12/2015 16:32

Dr Balaji Ganeshan, Director of New Business at Feedback Plc is to present a paper at the prestigious Society of Cardiac MR (SCMR) in January 2016. The paper’s abstract title is ‘CMR myocardial texture analysis tracks different etiologies of left ventricular hypertrophy’, and could lead to a new application in the field of cardiology for TexRAD following a study undertaken at UCL in collaboration with London Heart Hospital.